Rani Therapeutics Holdings (RANI) Treasury Shares (2020 - 2026)
Rani Therapeutics Holdings' (RANI) quarterly Treasury Shares came in at $225313.0 in Q1 2026, down 65.49% year-on-year from $652869.0 in Q1 2025, and down 35.39% quarter-over-quarter from $348702.0 in Q4 2025.
Rani Therapeutics Holdings (RANI) Treasury Shares (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Treasury Shares history runs 7 years deep, the most recent figure standing at $225313.0 for Q1 2026.
- On a quarterly basis, Treasury Shares fell 65.49% year-over-year to $225313.0 in Q1 2026; TTM through Mar 2026 was $225313.0, a 65.49% decrease from a year earlier, with the FY2025 full-year figure at $348702.0, down 57.05% from the prior year.
- Treasury Shares fell to $225313.0 in Q1 2026 per RANI's latest filing, from $348702.0 in the prior quarter.
- Across five years, Treasury Shares topped out at $970100.0 in Q2 2022 and bottomed at $3257.0 in Q4 2024.
- The 5-year median for Treasury Shares is $450694.0 (2025), against an average of $456335.2.
- Across the five-year window, Treasury Shares plunged 99.65% in 2022 and soared 10606.23% in 2025, its largest moves.
- Year by year, Treasury Shares stood at $665500.0 in 2022, then slumped by 94.95% to $33586.0 in 2023, then plunged by 90.3% to $3257.0 in 2024, then surged by 10606.23% to $348702.0 in 2025, then plunged by 35.39% to $225313.0 in 2026.
- Per Business Quant, the three latest RANI Treasury Shares figures stand at $225313.0 (Q1 2026), $348702.0 (Q4 2025), and $416305.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -21,709.08 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 265,401.92 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 19.41 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 5.14 Mn |
| 10 | Rani Therapeutics Holdings | 160.20 Mn | 167.33 Mn | - | 225,313.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 225,313.00 |
| Mar 31, 2026 | 225,313.00 |
| Dec 31, 2025 | 348,702.00 |
| Dec 31, 2025 | 348,702.00 |
| Sep 30, 2025 | 416,305.00 |
| Sep 30, 2025 | 416,305.00 |
| Jun 30, 2025 | 485,083.00 |
| Jun 30, 2025 | 485,083.00 |
| Mar 31, 2025 | 652,869.00 |
| Mar 31, 2025 | 652,869.00 |
| Dec 31, 2024 | 3,257.00 |
| Dec 31, 2024 | 3,257.00 |
| Sep 30, 2024 | 893,294.00 |
| Sep 30, 2024 | 893,294.00 |
| Dec 31, 2023 | 33,586.00 |
| Dec 31, 2023 | 33,586.00 |
| Dec 31, 2022 | 665,500.00 |
| Dec 31, 2022 | 665,500.00 |
| Sep 30, 2022 | 685,650.00 |
| Sep 30, 2022 | 685,650.00 |